This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Synthetic pentasaccharides

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • pentasaccharides are synthetic drugs that accelerate the interaction between factor Xa and antithrombin
    • induce a conformational change in antithrombin
      • unlike unfractionated and low-molecular-weight heparins, pentasaccharides do not affect the interaction of antithrombin with thrombin and thus selectively inhibit factor Xa activity
      • fondaparinux is a pentasaccharide with a half-life of approximately 17 hours
      • idraparinux is a long-acting pentassacharide, with a half-life of about 80 hours

A table comparing the properties of pentasaccarides to low molecular weight heparin is presented below:

Property

Pentasaccarides

Low molecular weight heparin

monitoring requirement

no*

no*

bioavailability

complete

very high

plasma protein binding

none

low

renal clearance

yes

yes

dose-dependent clearance

no

no

risk of heparin-induced thrombocytopaenia

no**

low

safety in pregnancy

not known

yes

route of administration

subcutaenous

subcutaneous

neutralised by protamine sulphate

no

partial

half-life (hours)

3-6 hours

fondaparinux 17 hours

* monitoring is required in patients with a creatinin clearance of less than 30 ml/min by anti-Xa concentrations.

** low-molecular-weight heparins are less likely to induce thrombocytopenia than unfractionated heparin, because these interact less with platelets and platelet factor 4 (an essential feature of heparin-induced thrombocytopenia). Pentasaccharides do not interact with platelet factor 4 and platelets and thus are very unlikely to induce thrombocytopaenia (1).

Trial evidence suggest that fondaparinux is as good as, and possibly better than, low molecular-weight heparin for the prophylaxis of post-operative deep venous thrombosis in patients undergoing hip replacement (2).

Reference:

  • (1) Savi P et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005;105 (1): 139-144.
  • (2) BMJ. 2006 Jan 28;332(7535):215-9.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page